{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:40:55Z","timestamp":1769848855802,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.mehy.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T20:03:56Z","timestamp":1491422636000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis"],"prefix":"10.1016","volume":"103","author":[{"given":"Sridharan","family":"Brindha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savariar","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devadasan","family":"Velmurugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanabalan","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish Chandrabose","family":"Sundaramurthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Joel","family":"Gnanadoss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2017.04.005_b0005","unstructured":"World Health Organization Global tuberculosis report. 20th ed.; 2015."},{"key":"10.1016\/j.mehy.2017.04.005_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tube.2016.06.006","article-title":"TBDRUGS \u2013 Database of drugs for tuberculosis","volume":"100","author":"Sundaramurthi","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.mehy.2017.04.005_b0015","unstructured":"World Health Organization. <http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/> [accessed 03.08.16]."},{"issue":"7","key":"10.1016\/j.mehy.2017.04.005_b0020","doi-asserted-by":"crossref","first-page":"e41367","DOI":"10.1371\/journal.pone.0041367","article-title":"Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India","volume":"7","author":"Viswanathan","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mehy.2017.04.005_b0025","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/bmjdrc-2015-000112","article-title":"Clinical profile of diabetes mellitus in tuberculosis","volume":"3","author":"Ogbera","year":"2015","journal-title":"BMJ Open Diabetes ResCare"},{"issue":"11","key":"10.1016\/j.mehy.2017.04.005_b0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/tmi.12198","article-title":"Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China","volume":"18","author":"Mi","year":"2013","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.mehy.2017.04.005_b0035","unstructured":"World Health Organization. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/44698\/1\/9789241502252_eng.pdf> [accessed 15.02.17]."},{"key":"10.1016\/j.mehy.2017.04.005_b0040","unstructured":"World Health Organization. <http:\/\/www.who.int\/tb\/areas-of-work\/treatment\/risk-factors\/en\/> [accessed 15.02.17]."},{"issue":"8","key":"10.1016\/j.mehy.2017.04.005_b0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new usesfor existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.mehy.2017.04.005_b0050","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/DDDT.S46289","article-title":"Open-source approaches for the repurposing of existing or failedcandidate drugs: learning from and applying the lessons across diseases","volume":"7","author":"Allarakhia","year":"2013","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"10.1016\/j.mehy.2017.04.005_b0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/nbt1007-1110","article-title":"Network pharmacology","volume":"25","author":"Hopkins","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.mehy.2017.04.005_b0060","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"7270","key":"10.1016\/j.mehy.2017.04.005_b0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/462167a","article-title":"Drug discovery: predicting promiscuity","volume":"462","author":"Hopkins","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2017.04.005_b0070","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1038\/srep06356","article-title":"Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing polypharmacological target selection","volume":"4","author":"Anand","year":"2014","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.mehy.2017.04.005_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2017.04.005_b0080","first-page":"297","article-title":"Systems approaches to polypharmacology and drugdiscovery","volume":"13","author":"Boran","year":"2010","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"7270","key":"10.1016\/j.mehy.2017.04.005_b0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mehy.2017.04.005_b0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/dks405","article-title":"Is repositioning of drugs a viable alternative in thetreatment of tuberculosis?","volume":"68","author":"Palomino","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.mehy.2017.04.005_b0095","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/jac\/dku166","article-title":"Simvastatin increases the in vivo activity of the first-line tuberculosis regimen","volume":"69","author":"Skerry","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.mehy.2017.04.005_b0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2014","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.mehy.2017.04.005_b0105","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1128\/AAC.01826-13","article-title":"Statins increase rifampin mycobactericidal effect","volume":"58","author":"Lobato","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"263","key":"10.1016\/j.mehy.2017.04.005_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.mehy.2017.04.005_b0115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201110-1769OC","article-title":"Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases","volume":"185","author":"Walker","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.mehy.2017.04.005_b0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijantimicag.2014.11.017","article-title":"Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis","volume":"45","author":"Gonzalo","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.mehy.2017.04.005_b0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.15252\/emmm.201404137","article-title":"Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion","volume":"7","author":"Schiebler","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"6685","key":"10.1016\/j.mehy.2017.04.005_b0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mehy.2017.04.005_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tim.2010.10.005","article-title":"Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery","volume":"19","author":"Ekins","year":"2011","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.mehy.2017.04.005_b0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tube.2011.08.006","article-title":"Informatics resources for tuberculosis\u2013towards drug discovery","volume":"92","author":"Sundaramurthi","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.mehy.2017.04.005_b0145","first-page":"697532","article-title":"In silico antitubercular activity analysis of benzofuran and naphthofuran derivatives","volume":"2014","author":"Karunakar","year":"2014","journal-title":"Tuberc Res Treat"},{"issue":"3","key":"10.1016\/j.mehy.2017.04.005_b0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/ci500672v","article-title":"A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA","volume":"55","author":"Perryman","year":"2015","journal-title":"J Chem Inf Model"},{"issue":"5","key":"10.1016\/j.mehy.2017.04.005_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0006-2013","article-title":"Mycobacterium tuberculosis Serine\/Threonine Protein Kinases","volume":"2","author":"Prisic","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.mehy.2017.04.005_b0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","article-title":"Genes required for mycobacterial growth defined by high density mutagenesis","volume":"48","author":"Sassetti","year":"2003","journal-title":"Mol Microbiol"},{"issue":"22","key":"10.1016\/j.mehy.2017.04.005_b0165","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1128\/JB.00963-06","article-title":"The Ser\/Thr protein kinase PknB is essential for sustaining mycobacterial growth","volume":"188","author":"Fernandez","year":"2006","journal-title":"J Bacteriol"},{"issue":"20","key":"10.1016\/j.mehy.2017.04.005_b0170","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1074\/jbc.M114.563536","article-title":"Protein kinase B (PknB) of Mycobacterium tuberculosis is essential for growth of the pathogen in vitro as well as for survival within the host","volume":"289","author":"Chawla","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.mehy.2017.04.005_b0175","doi-asserted-by":"crossref","first-page":"e1001746","DOI":"10.1371\/journal.pbio.1001746","article-title":"Mycobacterium tuberculosis Ser\/Thr protein kinase B mediates an oxygen-dependent replication switch","volume":"12","author":"Ortega","year":"2014","journal-title":"PLoS Biol"},{"issue":"14","key":"10.1016\/j.mehy.2017.04.005_b0180","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1101\/gad.1311105","article-title":"The Mycobacterium tuberculosis serine\/threonine kinases PknA and PknB: substrate identification and regulation of cell shape","volume":"19","author":"Kang","year":"2005","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.mehy.2017.04.005_b0185","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1016\/j.bmcl.2012.02.107","article-title":"Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis","volume":"22","author":"Chapman","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.mehy.2017.04.005_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mehy.2017.04.005_b0195","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mehy.2017.04.005_b0200","unstructured":"DrugBank. <www.drugbank.ca> [accessed 01.08.16]."},{"key":"10.1016\/j.mehy.2017.04.005_b0205","unstructured":"Protein Data Bank (PDB). <http:\/\/www.rcsb.org\/pdb\/home\/home.do> [accessed 15.04.15]."},{"issue":"13","key":"10.1016\/j.mehy.2017.04.005_b0210","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.febslet.2006.04.046","article-title":"The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria","volume":"580","author":"Wehenkel","year":"2006","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.mehy.2017.04.005_b0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.mehy.2017.04.005_b0220","unstructured":"PyRx. <http:\/\/pyrx.sourceforge.net\/> [accessed 15.04.15]."},{"issue":"18","key":"10.1016\/j.mehy.2017.04.005_b0225","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1039\/C6CP01555G","article-title":"Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power","volume":"18","author":"Wang","year":"2016","journal-title":"Phys Chem Chem Phys"},{"issue":"7","key":"10.1016\/j.mehy.2017.04.005_b0230","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.mehy.2017.04.005_b0235","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/ci400040d","article-title":"Docking challenge: protein sampling and molecular docking performance","volume":"53","author":"Elokely","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"1","key":"10.1016\/j.mehy.2017.04.005_b0240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mehy.2014.04.002","article-title":"Statin therapy may prevent development of tuberculosis in diabetic state","volume":"83","author":"Banerjee","year":"2014","journal-title":"Med Hypotheses"},{"issue":"6","key":"10.1016\/j.mehy.2017.04.005_b0245","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/fmb.10.50","article-title":"TMC207: the first compound of a new class of potent anti-tuberculosis drugs","volume":"5","author":"Matteelli","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.mehy.2017.04.005_b0250","doi-asserted-by":"crossref","unstructured":"Fiorillo M, Lamb R, Tanowitz HB, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany NY); 2016. [Epub ahead of print].","DOI":"10.18632\/aging.100983"},{"issue":"4","key":"10.1016\/j.mehy.2017.04.005_b0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tube.2011.03.005","article-title":"Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents","volume":"91","author":"Lougheed","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"issue":"22","key":"10.1016\/j.mehy.2017.04.005_b0260","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1016\/j.bmcl.2014.09.080","article-title":"Design, synthesis and molecular docking of substituted 3-hydrazinyl-3-oxo-propanamides as anti-tubercular agents","volume":"24","author":"Naqvi","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.mehy.2017.04.005_b0265","doi-asserted-by":"crossref","unstructured":"Gupta, Vivek, Naqvi, Asif, Tanwar, Jayendra, and Mishra, Kaushlesh. Molecular Modeling study of Protein Kinase PKnB from Mycobacterium Tuberculosis with derivatives of 1, 3, 4- Thiadiazoles. Available from Nature Precedings <http:\/\/hdl.handle.net\/10101\/npre.2011.6136.1>; 2011 [accessed 01.08.16].","DOI":"10.1038\/npre.2011.6136.1"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716306491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716306491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T12:43:16Z","timestamp":1719146596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716306491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":53,"alternative-id":["S0306987716306491"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.04.005","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}